Genetic and molecular basis of diabetic foot ulcers: Clinical review

Journal of Tissue Viability

Volumn 25, Issue 4, 2016, Pages 229-236

  Jhamb, Shaurya ^a   Vangaveti, Venkat N ^a   Malabu, Usman H ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Diabetic foot ulcer; Genetic and molecular aspects; Wound

Indexed keywords

CYTOKINE; DNA; GROWTH FACTOR; TOPICAL AGENT; UNTRANSLATED RNA; ANGIOGENIC FACTOR; MICRORNA;

CELL ACTIVATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETIC FOOT; DIABETIC NEUROPATHY; DNA METHYLATION; ENDOTHELIUM CELL; ETHNICITY; FIBROBLAST; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; HYPERBARIC OXYGEN THERAPY; HYPERGLYCEMIA; IMMUNE RESPONSE; KERATINOCYTE; MICROVASCULARIZATION; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; SHOCK WAVE THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN; SKIN TRANSPLANTATION; THROMBOCYTE; TOPICAL TREATMENT; VACUUM ASSISTED CLOSURE; WOUND HEALING; BACTERIAL INFECTION; COMPLICATION; GENE THERAPY; GENETIC EPIGENESIS; GENETICS; PATHOPHYSIOLOGY; RISK FACTOR;

ANGIOGENESIS INDUCING AGENTS; BACTERIAL INFECTIONS; DIABETIC FOOT; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC THERAPY; HUMANS; MICRORNAS; RISK FACTORS;

EID: 84977666977     PISSN: 0965206X     EISSN: 18764746     Source Type: Journal    
DOI: 10.1016/j.jtv.2016.06.005     Document Type: Review

References (101)

1. [1] Hoffstad, O., Mitra, N., Walsh, J., Margolis, D.J., Diabetes, lower-extremity amputation, and death. Diabetes Care 38:10 (2015 Oct), 1852–1857.
2. [2] Ahmad, N., Thomas, G.N., Gill, P., Chan, C., Torella, F., Lower limb amputation in England: prevalence, regional variation and relationship with revascularisation, deprivation and risk factors. A retrospective review of hospital data. J R Soc Med 107:12 (2014), 483–489.
3. [3] Clayton, W., Elasy, T.A., A review of the pathophysiology, classification, and treatment of foot ulcers in diabetic patients. Clin Diabetes 27:2 (2009), 52–58.
4. [4] Markakis, K., Bowling, F.L., Boulton, A.J., The diabetic foot in 2015: an overview. Diabetes Metab Res Rev 32:Suppl. 1 (2016), 169–178.
5. [5] Tapp, R.J., Shaw, J.E., de Courten, M.P., Dunstan, D.W., Welborn, T.A., Zimmet, P.Z., et al. Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med 20:2 (2003), 105–113.
6. [6] IDF. Diabetes Atlas Update 2015, International diabetes federation. 7th ed., 2015.
7. [7] Ray, J.A., Valentine, W.J., Secnik, K., Oglesby, A.K., Cordony, A., Gordois, A., et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 21:10 (2005), 1617–1629.
8. [8] Bowling, F.L., Rashid, S.T., Boulton, A.J., Preventing and treating foot complications associated with diabetes mellitus. Nat Rev Endocrinol 11:10 (2015), 606–616.
9. [9] Sinha, R., van den Heuvel, W.J., Arokiasamy, P., Factors affecting quality of life in lower limb amputees. Prosthet Orthot Int 35 (2011), 90–96.
10. [10] Malabu, U.H., Manickam, V., Kan, G., Doherty, S.L., Sangla, K.S., Calcific uremic arteriolopathy on multimodal combination therapy: still unmet goal. Int J Nephrol, 2012, 2012, 390768.
11. [11] Brem, H., Tomic-Canic, M., Cellular and molecular basis of wound healing in diabetes. J Clin Investig 117:5 (2007), 1219–1222.
12. [12] Jeffcoate, W.J., Harding, K.G., Diabetic foot ulcers. Lancet 361:9368 (2003), 1545–1551.
13. [13] Forstermann, U., Munzel, T., Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113 (2006), 1708–1714.
14. [14] El-Mesallamy, H.O., Hamdy, N.M., Ezzat, O.A., Reda, A.M., Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Investig Med 59:8 (2011), 1233–1238.
15. [15] Barrientos, S., Stojadinovic, O., Golinko, M.S., Brem, H., Tomic-Canic, M., Growth factors and cytokines in wound healing. Wound Repair Regen Official Publ Wound Heal Soc Eur Tissue Repair Soc 16:5 (2008), 585–601.
16. [16] Blakytny, R., Jude, E., The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 23:6 (2006), 594–608.
17. [17] Tayalia, P., Mooney, D.J., Controlled growth factor delivery for tissue engineering. Adv Mater (Deerf Beach, Fla) 21:32–33 (2009), 3269–3285.
18. [18] Madeddu, P., Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 90:3 (2005), 315–326.
19. [19] Baltzis, D., Eleftheriadou, I., Veves, A., Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther 31:8 (2014), 817–836.
20. [20] Perez-Zabala, E., Basterretxea, A., Larrazabal, A., Perez-Del-Pecho, K., Rubio-Azpeitia, E., Andia Biological approach for the management of non-healing diabetic foot ulcers. J Tissue Viability 25:2 (2016), 157–163.
21. [21] Edwards, R., Harding, K.G., Bacteria and wound healing. Curr Opin Infect Dis 17:2 (2004), 91–96.
22. [22] Singh, K., Agrawal, N.K., Gupta, S.K., Mohan, G., Chaturvedi, S., Singh, K., Genetic and epigenetic alterations in Toll like receptor 2 and wound healing impairment in type 2 diabetes patients. J Diabetes Complicat 29:2 (2015), 222–229.
23. [23] Y1, Xu, Zhou, Y., Lin, H., Hu, H., Wang, Y., Xu, G., Toll-like receptor 2 in promoting angiogenesis after acute ischemic injury. Int J Mol Med 31:3 (2013), 555–560.
24. [24] Ey, B., Eyking, A., Gerken, G., Podolsky, D.K., Cario, E., TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J Biol Chem 284:33 (2009), 22332–22343.
25. [25] Galkowska, H., Wojewodzka, U., Olszewski, W.L., Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound repair Regen 14:5 (2006), 558–565.
26. [26] Mat Saad, A.Z., Khoo, T.L., Halim, A.S., Wound bed preparation for chronic diabetic foot ulcers. ISRN Endocrinol, 2013, 2013, 608313.
27. [27] Galkowska, H., Olszewsk, W.L., Wojewodzka, U., Mijal, J., Filipiuk, E., Expression of apoptosis- and cell cycle-related proteins in epidermis of venous leg and diabetic foot ulcers. Surgery 134:2 (2003), 213–220.
28. [28] Catrina, S.B., Zheng, X., Disturbed hypoxic responses as a pathogenic mechanism of diabetic foot ulcers. Diabetes Metab Res Rev 32:Suppl. 1 (2016), 179–185.
29. [29] Earle, K., Walker, J., Hill, C., Viberti, G., Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N. Engl J Med 326:10 (1992), 673–677.
30. [30] Quinn, M., Angelico, M.C., Warram, J.H., Krolewski, A.S., Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:8 (1996), 940–945.
31. [31] Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46:11 (1997), 1829–1839.
32. [32] Abbott, C.A., Carrington, A.L., Ashe, H., Bath, S., Every, L.C., Griffiths, J., et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 19:5 (2002), 377–384.
33. [33] Lamont, P., Franklyn, K., Rayman, G., Boulton, A.J., Update on the diabetic foot 2012: the 14th biennial malvern diabetic foot conference, May 9-11, 2012. Int J Low Extrem Wounds 12:1 (2013), 71–75.
34. [34] Intine, R.V., Sarras, M.P. Jr., Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms. Curr diabetes Rep 12:5 (2012), 551–559.
35. [35] Berezin, A., Metabolic memory phenomenon in diabetes mellitus: achieving and perspectives. Diabetes Metab Syndr, 2016 pii: S1871-4021(16) 30005–4.
36. [36] Villeneuve, L.M., Reddy, M.A., Lanting, L.L., Wang, M., Meng, L., Natarajan, R., Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci U. S. A 105:26 (2008), 9047–9052.
37. [37] Caramori, M.L., Kim, Y., Moore, J.H., Rich, S.S., Mychaleckyj, J.C., Kikyo, N., et al. Gene expression differences in skin fibroblasts in identical twins discordant for type 1 diabetes. Diabetes 61:3 (2012), 739–744.
38. [38] Reddy, M.A., Zhang, E., Natarajan, R., Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 58:3 (2015), 443–455.
39. [39] Olsen, A.S., Sarras, M.P. Jr., Leontovich, A., Intine, R.V., Heritable transmission of diabetic metabolic memory in zebrafish correlates with DNA hypomethylation and aberrant gene expression. Diabetes 61:2 (2012), 485–491.
40. [40] Gao, C., Chen, G., Liu, L., Li, X., He, J., Jiang, L., et al. Impact of high glucose and proteasome inhibitor MG132 on histone H2A and H2B ubiquitination in rat glomerular mesangial cells. J Diabetes Res, 2013, 2013, 589474.
41. [41] Madhyastha, R., Madhyastha, H., Nakajima, Y., Omura, S., Maruyama, M., MicroRNA signature in diabetic wound healing: promotive role of miR-21 in fibroblast migration. Int Wound J 9:4 (2012), 355–361.
42. [42] Rafehi, H., El-Osta, A., Karagiannis, T.C., Epigenetic mechanisms in the pathogenesis of diabetic foot ulcers. J Diabetes Complicat 26:6 (2012), 554–561.
43. [43] Bruhn-Olszewska, B., Korzon-Burakowska, A., Gabig-Cimińska, M., Olszewski, P., Węgrzyn, A., Jakóbkiewicz-Banecka, J., Molecular factors involved in the development of diabetic foot syndrome. Acta Biochim Pol 59:4 (2012), 507–513.
44. [44] Gluckman, P.D., Hanson, M.A., Beedle, A.S., Non-genomic transgenerational inheritance of disease risk. BioEssays News Rev Mol Cell Dev Biol 29:2 (2007), 145–154.
45. [45] Whitelaw, N.C., Whitelaw, E., Transgenerational epigenetic inheritance in health and disease. Curr Opin Genet Dev 18:3 (2008), 273–279.
46. [46] Dolinoy, D.C., Jirtle, R.L., Environmental epigenomics in human health and disease. Environ Mol Mutagen 49:1 (2008), 4–8.
47. [47] Morgan, D.K., Whitelaw, E., The case for transgenerational epigenetic inheritance in humans. Mamm Genome Official J Int Mamm Genome Soc 19:6 (2008), 394–397.
48. [48] Blomen, V.A., Boonstra, J., Stable transmission of reversible modifications: maintenance of epigenetic information through the cell cycle. Cell Mol Life Sci CMLS 68:1 (2011), 27–44.
49. [49] Golledge, J., Biros, E., Bingley, J., Iyer, V., Krishna, S.M., Epigenetics and peripheral artery disease. Curr Atheroscler Rep., 18(4), 2016, 15, 10.1007/s11883-016-0567-4.
50. [50] Mosammaparast, N., Shi, Y., Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem 79 (2010), 155–179.
51. [51] Xu, J., Zgheib, C., Hu, J., Wu, W., Zhang, L., Liechty, K.W., The role of microRNA-15b in the impaired angiogenesis in diabetic wounds. Wound Repair Regen 22:5 (2014), 671–677.
52. [52] Madhyastha, R., Madhyastha, H., Nakajima, Y., Omura, S., Maruyama, M., MicroRNA signature in diabetic wound healing: promotive role of miR-21 in fibroblast migration. Int Wound J 9:4 (2012), 355–361.
53. [53] Leeper, N.J., Cooke, J.P., MicroRNA and mechanisms of impaired angiogenesis in diabetes mellitus. Circulation 123:3 (2011), 236–238.
54. [54] Rafehi, H., El-Osta, A., Karagiannis, T.C., Genetic and epigenetic events in diabetic wound healing. Int Wound J 8:1 (2011), 12–21.
55. [55] Sunkari, V.G., Lind, F., Botusan, I.R., Kashif, A., Liu, Z.J., Ylä-Herttuala, S., et al. Hyperbaric oxygen therapy activates hypoxia-inducible factor 1 (HIF-1), which contributes to improved wound healing in diabetic mice. Wound Repair Regen 23:1 (2015), 98–103.
56. [56] Biswas, S., Roy, S., Banerjee, J., Hussain, S.R., Khanna, S., Meenakshisundaram, G., et al. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci U. S. A 107 (2010), 6976–6981.
57. [57] Ramirez, H.A., Liang, L., Pastar, I., Rosa, A.M., Stojadinovic, O., Zwick, T.G., et al. Comparative genomic, microRNA, and tissue analyses reveal subtle differences between non-diabetic and diabetic foot skin. PLoS One, 10(8), 2015, e0137133.
58. [58] Moura, J., Børsheim, E., Carvalho, E., The role of microRNAs in diabetic complications-special emphasis on wound healing. Genes (Basel) 5:4 (2014), 926–956.
59. [59] Dasu, M.R., Ramirez, S.R., La, T.D., Gorouhi, F., Nguyen, C., Lin, B.R., et al. Crosstalk between adrenergic and toll-like receptors in human mesenchymal stem cells and keratinocytes: a recipe for impaired wound healing. Stem Cells Transl Med 3:6 (2014), 745–759.
60. [60] Sachidanandam, R., Weissman, D., Schmidt, S.C., Kakol, J.M., Stein, L.D., Marth, G., et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:6822 (2001), 928–933.
61. [61] Rizzo, A.E., Maibach, H.I., Personalizing dermatology: the future of genomic expression profiling to individualize dermatologic therapy. J Dermatol Treat 23:3 (2012), 161–167.
62. [62] Mu, H., Zhang, X.M., Liu, J.J., Dong, L., Feng, Z.L., Effect of high glucose concentration on VEGF and PEDF expression in cultured retinal Muller cells. Mol Biol Rep 36:8 (2009), 2147–2151.
63. [63] Amoli, M.M., Hasani-Ranjbar, S., Roohipour, N., Sayahpour, F.A., Amiri, P., Zahedi, P., et al. VEGF gene polymorphism association with diabetic foot ulcer. Diabetes Res Clin Pract 93:2 (2011), 215–219.
64. [64] Marsh, S., Nakhoul, F.M., Skorecki, K., Rubin, A., Miller, B.P., Leibu, R., et al. Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes care 23:9 (2000), 1375–1380.
65. [65] Shaw, T.J., Martin, P., Wound repair at a glance. J Cell Sci 122:Pt 18 (2009), 3209–3213.
66. [66] Watkins, S.A., Zippin, J.H., When wound healing goes awry. A review of normal and abnormal wound healing, scar pathophysiology, and therapeutics. J Drugs Dermatol JDD 7:10 (2008), 997–1005.
67. [67] Loot, M.A., Kenter, S.B., Au, F.L., van Galen, W.J., Middelkoop, E., Bos, J.D., et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 81:3 (2002), 153–160.
68. [68] Pichu, S., Sathiyamoorthy, J., Krishnamoorthy, E., Umapathy, D., Viswanathan, V., Impact of the hypoxia inducible factor-1α (HIF-1α) pro582ser polymorphism and its gene expression on diabetic foot ulcers. Diabetes Res Clin Pract 109:3 (2015), 533–540.
69. [69] Amin, N., Doupis, J., Diabetic foot disease: from the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities. World J Diabetes 7:7 (2016), 153–164.
70. [70] Mathieu, D.L.J.-C., Wattel, F., Handbook on hyperbaric medicine: non healing wounds. 2006, Springer, Netherlands.
71. [71] Gary Sibbald, R., Woo, K.Y., The biology of chronic foot ulcers in persons with diabetes. Diabetes Metab Res Rev 24:Suppl. 1 (2008), S25–S30 (S1).
72. [72] Gałkowska, H., Olszewski, W., Cellular and molecular basis of impaired healing of diabetic foot ulcers. Pol J Surg 79:11 (2007), 720–727.
73. [73] Falanga, V., Wound healing and its impairment in the diabetic foot. Lancet 366:9498 (2005), 1736–1743.
74. [74] Maruyama, K., Asai, J., Ii, M., Thorne, T., Losordo, D.W., D'Amore, P.A., Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol 170:4 (2007), 1178–1191.
75. [75] Gibran, N.S., Jang, Y.C., Isik, F.F., Greenhalgh, D.G., Muffley, L.A., Underwood, R.A., et al. Diminished neuropeptide levels contribute to the impaired cutaneous healing response associated with diabetes mellitus. J Surg Res 108:1 (2002), 122–128.
76. [76] Stojadinovic, O., Brem, H., Vouthounis, C., Lee, B., Fallon, J., Stallcup, M., et al. Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing. Am J Pathol 167:1 (2005), 59–69.
77. [77] Bergin, S.M., Gurr, J.M., Allard, B.P., Holland, E.L., Horsley, M.W., Kamp, M.C., et al. Australian Diabetes Foot Network: management of diabetes-related foot ulceration - a clinical update. Med J Aust 197:4 (2012), 226–229.
78. [78] Barrientos, S., Brem, H., Stojadinovic, O., Tomic-Canic, M., Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen 22:5 (2014), 569–578.
79. [79] Yeboah, A., Cohen, R.I., Faulknor, R., Schloss, R., Yarmush, M.L., Berthiaume, F., The development and characterization of SDF1α-elastin-like-peptide nanoparticles for wound healing. J Control Release, 2016 pii: S0168–3659(16)30222-X.
80. [80] Saboo, A., Rathnayake, A., Vangaveti, V.N., Malabu, U.H., Wound healing effects of dipeptidyl peptidase-4 inhibitors: an emerging concept in management of diabetic foot ulcer-a review. Diabetes Metab Syndr 10:2 (2016), 113–119, 10.1016/j.dsx.2015.04.006.
81. [81] Johnston, B.R., Ha, A.Y., Brea, B., Liu, P.Y., The mechanism of hyperbaric oxygen therapy in the treatment of chronic wounds and diabetic foot ulcers. R I Med J (2013) 99:2 (2016), 24–27.
82. [82] Blume, P.A., Walters, J., Payne, W., Ayala, J., Lantis, J., Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes care 31:4 (2008), 631–636.
83. [83] Isaac, A.L., Armstrong, D.G., Negative pressure wound therapy and other new therapies for diabetic foot ulceration: the current state of play. Med Clin North Am 97:5 (2013), 899–909.
84. [84] Etöz, A., The use of negative pressure wound therapy on diabetic foot ulcers: a preliminary controlled trial. Wounds (King Prussia, Pa) 16 (2004), 264–269.
85. [85] Lobmann, R., Zemlin, C., Motzkau, M., Reschke, K., Lehnert, H., Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complicat 20:5 (2006), 329–335.
86. [86] Grek, C.L., Prasad, G.M., Viswanathan, V., Armstrong, D.G., Gourdie, R.G., Ghatnekar, G.S., Topical administration of a connexin43-based peptide augments healing of chronic neuropathic diabetic foot ulcers: a multicenter, randomized trial. Wound Repair Regen 23:2 (2015 Mar-Apr), 203–212.
87. [87] Omar, M.T., Alghadir, A., Al-Wahhabi, K.K., Al-Askar, A.B., Efficacy of shock wave therapy on chronic diabetic foot ulcer: a single-blinded randomized controlled clinical trial. Diabetes Res Clin Pract 106:3 (2014), 548–554.
88. [88] Wang, C.J., Wu, C.T., Yang, Y.J., Liu, R.T., Kuo, Y.R., Long-term outcomes of extracorporeal shockwave therapy for chronic foot ulcers. J Surg Res 189:2 (2014), 366–372.
89. [89] Schaden, W., Thiele, R., Kolpl, C., Pusch, M., Nissan, A., Attinger, C.E., et al. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study. J Surg Res 143:1 (2007), 1–12.
90. [90] Contaldo, C., Hogger, D.C., Khorrami Borozadi, M., Stotz, M., Platz, U., Forster, N., et al. Radial pressure waves mediate apoptosis and functional angiogenesis during wound repair in ApoE deficient mice. Microvasc Res 84:1 (2012), 24–33.
91. [91] Baltzis, D., Eleftheriadou, I., Veves, A., Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther 31:8 (2014), 817–836.
92. [92] Jansen, F., Yang, X., Hoelscher, M., Cattelan, A., Schmitz, T., Proebsting, S., et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 128:18 (2013), 2026–2038.
93. [93] Shu, Y., Pi, F., Sharma, A., Rajabi, M., Haque, F., Shu, D., et al. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv Drug Deliv Rev 66 (2014), 74–89.
94. [94] Park, C.Y., Choi, Y.S., McManus, M.T., Analysis of microRNA knockouts in mice. Hum Mol Genet 19 (2010), R169–R175.
95. [95] Ruberti, F., Barbato, C., Cogoni, C., Targeting microRNAs in neurons: tools and perspectives. Exp Neurol 235 (2012), 419–426.
96. [96] Ojalvo, A.G., Acosta, J.B., Marí, Y.M., Mayola, M.F., Pérez, C.V., Gutiérrez, W.S., et al. Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction. Int Wound J, 2016, 10.1111/iwj.12592.
97. [97] Zhang, Z., Lv, L., Effect of local insulin injection on wound vascularization in patients with diabetic foot ulcer. Exp Ther Med 11:2 (2016), 397–402.
98. [98] Xu, S.M., Liang, T., Clinical observation of the application of autologous peripheral blood stem cell transplantation for the treatment of diabetic foot gangrene. Exp Ther Med 11:1 (2016), 283–288.
99. [99] Dubsky, M., Jirkovska, A., Bem, R., Fejfarova, V., Pagacova, L., Sixta, B., et al. Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes Metab Res Rev 29:5 (2013), 369–376.
100. [100] Humpert, P.M., Bartsch, U., Konrade, I., Hammes, H.P., Morcos, M., Kasper, M., et al. Locally applied mononuclear bone marrow cells restore angiogenesis and promote wound healing in a type 2 diabetic patient. Exp Clin Endocrinol Diabetes 113:9 (2005), 538–540.
101. [101] Brem, H., Kodra, A., Golinko, M.S., Entero, H., Stojadinovic, O., Wang, V.M., et al. Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Investig Dermatol 129:9 (2009), 2275–2287.